首页> 外国专利> direct molecular diagnosis of friedreich ataxia

direct molecular diagnosis of friedreich ataxia

机译:Friedreich共济失调的直接分子诊断

摘要

This invention relates generally to methods for the diagnosis and therapeutic treatment of Friedreich Ataxia. Friedreich ataxia (FRDA) is an autosomal recessive, degenerative disease that involves the central and peripheral nervous system and the heart. A gene, X25, was identified in the critical region for the FRDA locus on chromosome 9q13. The gene encodes a 210 amino acid protein, frataxin, that has homologues in distant species such as C. elegans and yeast. A few FRDA patients have been found to have point mutations in X25, but the vast majority are homozygous for a variable, unstable GAA trinucleotide expansion in the first X25 intron. Mature X25 mRNA was severely reduced in abundance in individuals with FRDA. Carriers and individuals at risk for developing FRDA can be ascertained by the methods of the present invention. Further, the methods of the present invention provide treatment to those individuals having FRDA.
机译:本发明总体上涉及腓特烈共济失调的诊断和治疗方法。 Friedreich共济失调(FRDA)是一种常染色体隐性遗传退化性疾病,涉及中枢神经系统和周围神经系统以及心脏。在染色体9q13上FRDA基因座的关键区域鉴定出X25基因。该基因编码一个210个氨基酸的蛋白,frataxin,它在遥远的物种(如秀丽隐杆线虫和酵母)中具有同源性。已经发现一些FRDA患者在X25中具有点突变,但是绝大多数在第一个X25内含子中对于可变的,不稳定的GAA三核苷酸扩增是纯合的。 FRDA患者体内成熟X25 mRNA的丰度大大降低。可以通过本发明的方法确定具有发展FRDA风险的载体和个体。此外,本发明的方法为患有FRDA的个体提供治疗。

著录项

相似文献

  • 专利
  • 外文文献
  • 中文文献
获取专利

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号